Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters








Language
Year range
1.
Chinese Medical Journal ; (24): 634-638, 2022.
Article in English | WPRIM | ID: wpr-927551

ABSTRACT

Inflammatory bowel disease (IBD) is a non-specific inflammatory disease of the gastrointestinal (GI) tract that is generally accepted to be closely related to intestinal dysbiosis in the host. GI infections contribute a key role in the pathogenesis of IBD; however, although the results of recent clinical studies have revealed an inverse correlation between Helicobacter pylori (H. pylori) infection and IBD, the exact mechanism underlying the development of IBD remains unclear. H. pylori, as a star microorganism, has been a focus for decades, and recent preclinical and real-world studies have demonstrated that H. pylori not only affects the changes in the gastric microbiota and microenvironment but also influences the intestinal microbiota, indicating a potential correlation with IBD. Detailed analysis revealed that H. pylori infection increased the diversity of the intestinal microbiota, reduced the abundance of Bacteroidetes, augmented the abundance of Firmicutes, and produced short-chain fatty acid-producing bacteria such as Akkermansia. All these factors may decrease vulnerability to IBD. Further studies investigating the H. pylori-intestinal microbiota metabolite axis should be performed to understand the mechanism underlying the development of IBD.


Subject(s)
Chronic Disease , Dysbiosis/microbiology , Gastrointestinal Microbiome , Helicobacter Infections , Helicobacter pylori , Humans , Inflammatory Bowel Diseases/microbiology , Microbiota
2.
Gac. méd. Méx ; 155(5): 447-452, Sep.-Oct. 2019. tab, graf
Article in English | LILACS | ID: biblio-1286541

ABSTRACT

Introduction: Common variable immunodeficiency (CVID) is the main symptomatic primary immunodeficiency and is associated with complex immune disorders. Gut microbiota interacts closely with the immune system, and intestinal dysbiosis is related to multiple diseases. Objective: To describe for the first time the composition of gut microbiota in Mexican patients with CVID. Methods: Fecal samples from five patients with CVID were collected and massive sequencing of the V3-V4 region of 16S rRNA gene was carried out using illumina technology. Results: Bacterial relative abundance was observed at all taxonomic levels. Firmicutes, Actinobacteria and Verrucomicrobia were the predominant phyla. The Clostridia class and the Clostridial order were the most common in their respective taxon; the Ruminococcaceae family predominated. A total of 166 genera were reported, with the most abundant being Faecalibacterium. Five species were identified, but only Bifidobacterium longum was present in all patients. Conclusions: Unlike healthy subjects' gut microbiota, where Firmicutes and Bacteroidetes predominate, the microbiota of the patients with CVID considered in this study was abundant in Firmicutes, Actinobacteria and Verrucomicrobia. The low presence of Bacteroidetes and high abundance of Firmicutes might indicate the existence of intestinal dysbiosis in these patients.


Subject(s)
Humans , Adult , Common Variable Immunodeficiency/microbiology , Gastrointestinal Microbiome/immunology , Bacteria/classification , RNA, Ribosomal, 16S/genetics , Actinobacteria/isolation & purification , Clostridium/isolation & purification , Bacteroidetes/isolation & purification , Ruminococcus/isolation & purification , Feces/microbiology , Verrucomicrobia/isolation & purification , Dysbiosis/immunology , Dysbiosis/microbiology , Firmicutes/isolation & purification , Clostridiales/isolation & purification , Faecalibacterium/isolation & purification , Bifidobacterium longum/isolation & purification , Mexico
3.
Yonsei Medical Journal ; : 4-12, 2018.
Article in English | WPRIM | ID: wpr-742511

ABSTRACT

The intestinal microbiota is a complex ecosystem consisting of various microorganisms that expands human genetic repertoire and therefore affects human health and disease. The metabolic processes and signal transduction pathways of the host and intestinal microorganisms are intimately linked, and abnormal progression of each process leads to changes in the intestinal environment. Alterations in microbial communities lead to changes in functional structures based on the metabolites produced in the gut, and these environmental changes result in various bacterial infections and chronic enteric inflammatory diseases. Here, we illustrate how antibiotics are associated with an increased risk of antibiotic-associated diseases by driving intestinal environment changes that favor the proliferation and virulence of pathogens. Understanding the pathogenesis caused by antibiotics would be a crucial key to the treatment of antibiotic-associated diseases by mitigating changes in the intestinal environment and restoring it to its original state.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Bacteria/growth & development , Dysbiosis/microbiology , Gastrointestinal Microbiome/drug effects , Humans , Intestines/drug effects , Intestines/microbiology , Symbiosis/drug effects
4.
Clin. biomed. res ; 34(3): 245-252, 2014. ilus
Article in English | LILACS | ID: biblio-834470

ABSTRACT

Several trillions of bacteria, distributed among more than 1,000 species, are natural inhabitants of the human intestinal tract and constitute what is now known as the gut microbiota. Although its composition varies within and between individuals with age, diet, and health status, it is becoming increasingly recognized that imbalances in the bacterial microbiota (dysbiosis) are linked to a number of conditions such as antibiotic-associated diarrhea, inflammatory bowel disease, and obesity, among others. Fecal transplantation where a preparation of stool from a microbiologically screened donor is administered into the colon of an affected recipient has been shown to be highly effective for the treatment of recurrent Clostridium difficile infection. Several trials of this therapy are now underway for gut dysbiosis in a number of patient disease groups raising concerns on the risk of transmission of infectious agents from donor to recipient, possible long-term adverse consequences of treatment, and effective regulation of the stool material used for the procedure. A worrying aspect is the emergence of private stool banks providing samples to the general public for self-administration.


Subject(s)
Humans , Dysbiosis/microbiology , Dysbiosis/therapy , Inflammatory Bowel Diseases/therapy , Microbiota , Biological Therapy/methods , Biological Therapy , Biological Specimen Banks , Clostridioides difficile , Donor Selection , Inflammatory Bowel Diseases/microbiology , Inflammatory Bowel Diseases/drug therapy , Feces/microbiology , Intestines/microbiology , Biological Therapy/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL